Cilostazol Inhibits Leukocyte Integrin Mac-1, Leading to a Potential Reduction in Restenosis After Coronary Stent Implantation

Perspectives in Vascular Surgery and Endovascular Therapy

Volumn 17, Issue 3, 2005, Pages 265-267

  Sumpio, Bauer E ^a   Aruny, John ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cilostazol; platelets; stent restenosis

Indexed keywords

EID: 84993812333     PISSN: 15310035     EISSN: None     Source Type: Journal    
DOI: 10.1177/153100350501700317     Document Type: Article

References (14)

1. Farb A, Burke A.P., Kolodgie F.D., et al: Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108:1701-1706, 2003.
2. Welt F.G., Rogers C: Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22:1769-1776, 2002.
3. Lau K, Mak K, Hung J, et al: Structural nuances in stent design, composition and coating may have a structural influence on the degree of arterial wall reaction. Am Heart J 147:764-773, 2004.
4. Sumpio BE. Atherosclerosis: biological and surgical considerations. In Ascher E, Hollier L, Strandness D.E., editors: Haimovici's Vascular Surgery, 5th edition. Malden, MA: Blackwell Science, Inc; pp 137-163, 2004.
5. Kambayashi J, Liu Y, Sun B, et al: Cilostazol as a unique anti-thrombotic agent. Curr Pharm Des 9(28): 2289-2302, 2003.
6. Rybalkin S.D., Bornfeldt KE: Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost 82, 424-434, 1999.
7. Takahashi S, Oida K, Fujiwara R, et al: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 20, 900-906, 1992.
8. Park S.W., Lee C.W., Kim H.S., et al: Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 86:499-503, 2000.
9. Sekiya M.J., Funada K, Watanabe M, et al: Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 82:144-147, 1998.
10. Take S.M., Matsutani H, Ueda H, et al: Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 79:1097-1099, 1997.
11. Tsuchikane E, Fukuhara A, Kobayashi T, et al: Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 100, 21-26, 1999.
12. Yamasaki M, Hara K, Ikari Y, et al: Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn 44, 387-391, 1998.
13. Weintraub W.S., Foster J, Culler S.D., et al, Cilostazol for RESTenosis trial: Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial. J Invasive Cardiol 16(5):257-259, 2004.
14. Inoue T, Sohma R, Morooka S. Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thromb Res 93, 137-143, 1999.